News & Updates
Filter by Specialty:
MTX treatment break improves COVID-19 booster response in patients with IMIDs
In individuals with immune-mediated inflammatory diseases (IMIDs*), a 2-week interruption in methotrexate (MTX) treatment led to enhanced COVID-19 booster vaccine response compared with those who continued with MTX treatment, according to findings from the VROOM** study.
MTX treatment break improves COVID-19 booster response in patients with IMIDs
18 Aug 2022
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
12 Aug 2022
1 week off methotrexate works okay for RA patients receiving flu shot
Temporarily discontinuing methotrexate treatment for 1 week appears to induce satisfactory response to a seasonal influenza vaccine in patients with rheumatoid arthritis (RA), with a similar effect as a 2-week interruption schedule, according to a study.
1 week off methotrexate works okay for RA patients receiving flu shot
11 Aug 2022
Men with PsA derive more benefit from MTX+ETN therapy than women
Combination therapy with methotrexate (MTX) plus etanercept (ETN) results in more improved outcomes in men than in women with psoriatic arthritis (PsA) for minimal disease activity (MDA) and Psoriatic Arthritis Disease Activity Score (PASDAS), a study has shown.
Men with PsA derive more benefit from MTX+ETN therapy than women
09 Aug 2022
Apremilast more efficacious in PsA patients with moderate vs high disease activity
Psoriatic arthritis (PsA) patients with moderate disease activity (MDA) at baseline who are treated with apremilast are more likely to achieve treatment targets than those with high disease activity (HDA), a recent study has shown.